![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » electroCore Snags New Use Indication for Portable Migraine Therapy Technology
electroCore Snags New Use Indication for Portable Migraine Therapy Technology
![](https://www.fdanews.com/ext/resources/test/Device_Images6/electroCore_Logo.png?t=1585950458&width=430)
January 31, 2018
Bioelectronic medicine company electroCore achieved 510(k) clearance from the FDA for a new use indication on its gammaCore therapy technology.
The new clearance allows for the noninvasive neuromodulation treatment to be used for treating acute migraine-associated pain in adult patients. The FDA previously cleared gammaCore for treating pain associated with adult episodic cluster headache.
Self-administered treatment can be delivered through a hand-held unit designed to provide mild electric stimulation to the vagus nerves through a patient’s skin.
Upcoming Events
-
21Oct